CN102626396A - 一种美托洛尔缓释片剂及其制备方法 - Google Patents
一种美托洛尔缓释片剂及其制备方法 Download PDFInfo
- Publication number
- CN102626396A CN102626396A CN2012101329286A CN201210132928A CN102626396A CN 102626396 A CN102626396 A CN 102626396A CN 2012101329286 A CN2012101329286 A CN 2012101329286A CN 201210132928 A CN201210132928 A CN 201210132928A CN 102626396 A CN102626396 A CN 102626396A
- Authority
- CN
- China
- Prior art keywords
- tablet
- plastic material
- metoprolol
- piller
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 235000010603 pastilles Nutrition 0.000 claims abstract description 99
- 229960002237 metoprolol Drugs 0.000 claims abstract description 74
- 239000003814 drug Substances 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 62
- 239000000463 material Substances 0.000 claims abstract description 61
- 229920003023 plastic Polymers 0.000 claims abstract description 45
- 239000004033 plastic Substances 0.000 claims abstract description 45
- 238000000576 coating method Methods 0.000 claims abstract description 20
- 230000008569 process Effects 0.000 claims abstract description 15
- 239000003826 tablet Substances 0.000 claims description 104
- 238000004090 dissolution Methods 0.000 claims description 100
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 26
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 26
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 26
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 26
- 239000007939 sustained release tablet Substances 0.000 claims description 26
- 235000010980 cellulose Nutrition 0.000 claims description 19
- 229920002678 cellulose Polymers 0.000 claims description 19
- 239000001913 cellulose Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 11
- 239000007779 soft material Substances 0.000 claims description 10
- 125000005456 glyceride group Chemical group 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims description 6
- 239000007766 cera flava Substances 0.000 claims description 5
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000005563 spheronization Methods 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000006187 pill Substances 0.000 abstract 3
- 239000012530 fluid Substances 0.000 description 33
- 238000003756 stirring Methods 0.000 description 33
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 30
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000001856 Ethyl cellulose Substances 0.000 description 17
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 17
- 229920001249 ethyl cellulose Polymers 0.000 description 17
- 235000019325 ethyl cellulose Nutrition 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- ZBOQQGAVXCUYJM-UHFFFAOYSA-N butanedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical group OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 ZBOQQGAVXCUYJM-UHFFFAOYSA-N 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 238000001816 cooling Methods 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- 239000012738 dissolution medium Substances 0.000 description 8
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 8
- -1 hydroxypropyl Chemical group 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 238000007613 slurry method Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000001069 triethyl citrate Substances 0.000 description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 6
- 235000013769 triethyl citrate Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003361 porogen Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000887 spectinomycin hydrochloride Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210132928.6A CN102626396B (zh) | 2012-04-28 | 2012-04-28 | 一种美托洛尔缓释片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210132928.6A CN102626396B (zh) | 2012-04-28 | 2012-04-28 | 一种美托洛尔缓释片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102626396A true CN102626396A (zh) | 2012-08-08 |
CN102626396B CN102626396B (zh) | 2014-05-07 |
Family
ID=46584904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210132928.6A Active CN102626396B (zh) | 2012-04-28 | 2012-04-28 | 一种美托洛尔缓释片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102626396B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074553A (zh) * | 2016-06-13 | 2016-11-09 | 杭州华东医药集团新药研究院有限公司 | 含有西格列汀和二甲双胍的药物组合物 |
CN107666913A (zh) * | 2015-03-03 | 2018-02-06 | 萨尼奥纳有限责任公司 | 特索芬辛,β‑受体阻滞剂组合制剂 |
CN108553430A (zh) * | 2018-05-22 | 2018-09-21 | 远大医药(中国)有限公司 | 一种酒石酸美托洛尔片及其制备方法 |
CN110420196A (zh) * | 2019-09-04 | 2019-11-08 | 西安科力康医药科技有限公司 | 一种酒石酸美托洛尔缓释制剂的制备方法 |
CN111166725A (zh) * | 2020-01-18 | 2020-05-19 | 东莞市东阳光仿制药研发有限公司 | 一种美托洛尔缓释片剂组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050008701A1 (en) * | 2003-07-11 | 2005-01-13 | Mongkol Sriwongjanva | Formulation and process for drug loaded cores |
-
2012
- 2012-04-28 CN CN201210132928.6A patent/CN102626396B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050008701A1 (en) * | 2003-07-11 | 2005-01-13 | Mongkol Sriwongjanva | Formulation and process for drug loaded cores |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107666913A (zh) * | 2015-03-03 | 2018-02-06 | 萨尼奥纳有限责任公司 | 特索芬辛,β‑受体阻滞剂组合制剂 |
US10828278B2 (en) | 2015-03-03 | 2020-11-10 | Saniona A/S | Tesofensine and beta blocker combination formulations |
CN107666913B (zh) * | 2015-03-03 | 2021-11-26 | 萨尼奥纳有限责任公司 | 特索芬辛,β-受体阻滞剂组合制剂 |
US11426383B2 (en) | 2015-03-03 | 2022-08-30 | Saniona A/S | Tesofensine and beta blocker combination formulations |
US12016840B2 (en) | 2015-03-03 | 2024-06-25 | Saniona A/S | Tesofensine and beta blocker combination formulations |
CN106074553A (zh) * | 2016-06-13 | 2016-11-09 | 杭州华东医药集团新药研究院有限公司 | 含有西格列汀和二甲双胍的药物组合物 |
CN106074553B (zh) * | 2016-06-13 | 2019-02-22 | 杭州华东医药集团新药研究院有限公司 | 含有西格列汀和二甲双胍的药物组合物 |
CN108553430A (zh) * | 2018-05-22 | 2018-09-21 | 远大医药(中国)有限公司 | 一种酒石酸美托洛尔片及其制备方法 |
CN110420196A (zh) * | 2019-09-04 | 2019-11-08 | 西安科力康医药科技有限公司 | 一种酒石酸美托洛尔缓释制剂的制备方法 |
CN111166725A (zh) * | 2020-01-18 | 2020-05-19 | 东莞市东阳光仿制药研发有限公司 | 一种美托洛尔缓释片剂组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102626396B (zh) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102036654B (zh) | 稳定的非典型抗精神病制剂 | |
CN101862297B (zh) | 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法 | |
TW422708B (en) | Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract | |
CN102626396B (zh) | 一种美托洛尔缓释片剂及其制备方法 | |
CN86106588A (zh) | 新的药物制剂 | |
WO2006115198A1 (ja) | 多孔質セルロース凝集体及びその成型体組成物 | |
JP2008507508A (ja) | トピラメート徐放性製剤及びその製造方法 | |
JP2011516527A (ja) | 医薬品有効成分の造粒 | |
CN102883713A (zh) | 耐醇型制剂 | |
CN104814923B (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
CN103751137B (zh) | 雷诺嗪多单元缓释微丸片 | |
WO2017170854A1 (ja) | 有効成分の化学的安定性に優れたフィルムコーティング錠 | |
CN105769773A (zh) | 洛索洛芬钠缓释微丸 | |
CN103169685B (zh) | 一种丁苯酞控释制剂及其制备方法 | |
CN101874817A (zh) | 鸦胆子油肠溶微囊及其制备方法和应用 | |
CN105816436B (zh) | 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法 | |
CN104274387A (zh) | 美托洛尔缓释组合物 | |
CN102406619A (zh) | 一种缓释微丸及其制备方法 | |
CN103655585A (zh) | 一种天麻素控释制剂及其制备方法 | |
CN102440963A (zh) | 一种别嘌醇缓释微丸及其制备方法 | |
CN102921008B (zh) | 一种含有钙阻滞剂的药物组合物 | |
CN102579392A (zh) | 一种含有盐酸坦索罗辛的缓释制剂及其制备方法 | |
CN1191831C (zh) | 复方阿替洛尔硝苯地平缓释制剂 | |
CN101647782A (zh) | 长春西汀口服自微乳化微丸及其制备和应用 | |
CN103040759A (zh) | 一种以维格列汀为活性成分的缓释口服固体制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Honggang Inventor after: Tan Haisong Inventor after: He Yanni Inventor after: Meng Xuexuan Inventor after: Fu Xuanjin Inventor after: Jia Qiang Inventor before: Zhu Honggang Inventor before: Tan Haisong Inventor before: He Yanni Inventor before: Zhao Lanmin Inventor before: Zhang Songqiong Inventor before: Li Jiqing Inventor before: Xu Yan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHU HONGGANG TAN HAISONG HE YANNI ZHAO LANMIN ZHANG SONGQIONG LI JIQING XU YAN TO: ZHU HONGGANG TAN HAISONG HE YANNI MENG XUEXUAN FU XUANJIN JIA QIANG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Haikou standard structure building 570, No. 3113, Haikou Industrial Park, Haikou, Haixin high tech Zone, Hainan Province Patentee after: Huayi Taikang Pharmaceutical Co.,Ltd. Address before: 570314 Building D, Haikou high tech Zone, No. 273, Nanhai Avenue, Haikou City, Hainan Province Patentee before: HAINAN VISUM PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A metoprolol sustained-release tablet and its preparation method Effective date of registration: 20230727 Granted publication date: 20140507 Pledgee: Industrial Bank Co.,Ltd. Haikou Branch Pledgor: Huayi Taikang Pharmaceutical Co.,Ltd. Registration number: Y2023980049959 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |